Department of General Surgery, Taizhou First People's Hospital, Taizhou, China.
Dis Markers. 2022 Aug 23;2022:6734105. doi: 10.1155/2022/6734105. eCollection 2022.
The prognosis of gastric cancer (GC) is difficult to predict due to the disease's complex genetic and phenotypic characteristics. MUC16 has been reported to be involved in the progression of several tumors. In this study, we aimed to explore whether MUC16 mutation had any impact on the prognosis or treatments of GC patients. Additionally, this analysis uncovered possible critical pathways related with these systems. On the cBioPortal, we were able to locate the pertinent data of patients with MUC16 mutations. And then, GSEA analysis identified differences in mRNA levels between mutant and wild-type MUC16 patients in terms of biological function annotation and pathways. The KEGG and GO analyses were also performed using the differentially expressed genes (DEGs). There were 139 individuals with GC who had the MUC16 mutation, which accounts for 32 percent, and the remaining patients had the MUC16 wild type. Survival assays revealed that patients with the MUC16 mutation had longer overall survival and disease-free survival. GSEA analysis revealed that cell cycle, cysteine and methionine metabolism, Huntington's disease, one carbon pool by folate, pyrimidine metabolism, pyruvate metabolism, RNA degradation, spliceosome, and valine leucine and isoleucine degradation were distinctly enriched in patients with MUC16 mutation type. Moreover, we identified 323 DEGs. Among them, 162 genes were upregulated, and 161 genes were downregulated. GO and KEGG assays indicated DEGs as enriched in pancreatic secretion, neuroactive ligand-receptor interaction, protein digestion and absorption, fat digestion and absorption, and glycerolipid metabolism. Overall, our data revealed that the MUC16 mutation in GC may affect the development of patients by altering several genes and pathways, indicating the importance of MUC16 mutation in the treatments of GC on an individual basis.
由于胃癌（GC）的疾病具有复杂的遗传和表型特征，因此其预后难以预测。MUC16 已被报道参与了几种肿瘤的进展。在这项研究中，我们旨在探讨 MUC16 突变是否对 GC 患者的预后或治疗有任何影响。此外，该分析还揭示了与这些系统相关的可能关键途径。在 cBioPortal 上，我们能够找到 MUC16 突变患者的相关数据。然后，GSEA 分析根据生物学功能注释和途径，确定了突变型和野生型 MUC16 患者之间的 mRNA 水平差异。使用差异表达基因（DEGs）还进行了 KEGG 和 GO 分析。有 139 名 GC 患者存在 MUC16 突变，占 32%，其余患者为 MUC16 野生型。生存分析表明，MUC16 突变患者的总生存期和无病生存期更长。GSEA 分析表明，细胞周期、半胱氨酸和蛋氨酸代谢、亨廷顿病、叶酸单碳池、嘧啶代谢、丙酮酸代谢、RNA 降解、剪接体、缬氨酸亮氨酸和异亮氨酸降解在 MUC16 突变型患者中明显富集。此外，我们还鉴定了 323 个 DEGs。其中，162 个基因上调，161 个基因下调。GO 和 KEGG 分析表明，DEGs 富集在胰腺分泌、神经活性配体-受体相互作用、蛋白质消化吸收、脂肪消化吸收和甘油磷脂代谢中。总的来说，我们的数据表明，GC 中的 MUC16 突变可能通过改变几个基因和途径来影响患者的发展，这表明 MUC16 突变在 GC 个体化治疗中的重要性。
